Bone Biologics Corp (BBLGW) Gains from Investment Securities (2023 - 2025)

Bone Biologics (BBLGW) has reported Gains from Investment Securities for 3 consecutive years, with -$498.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Gains from Investment Securities rose 96.16% year-over-year to -$498.0; the TTM figure through Dec 2025 stood at -$3967.0 (up 92.23% YoY), while the FY2025 annual figure was -$3967.0, up 92.23% from the prior year.
• Gains from Investment Securities grew to -$498.0 in Q4 2025 per BBLGW's latest filing, from -$1212.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $562918.0 in Q1 2023 and bottomed at -$1.3 million in Q2 2023.
• Historically, Gains from Investment Securities has averaged -$78978.3 across 3 years, with a median of -$6070.0 in 2024.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 106.21% — and 2025, when it slumped 112.15%.
• Bone Biologics' Gains from Investment Securities stood at -$24763.0 in 2023, then jumped by 47.67% to -$12959.0 in 2024, then jumped by 96.16% to -$498.0 in 2025.
• Business Quant data shows BBLGW's Gains from Investment Securities at -$498.0 in Q4 2025, -$1212.0 in Q3 2025, and -$902.0 in Q2 2025.